FORWARD PHARMA A/S AND THE BANK OF NEW YORK MELLONDeposit Agreement • March 25th, 2015 • Forward Pharma a/S • Pharmaceutical preparations • New York
CONVERTIBLE LOAN AGREEMENT BETWEEN Forward Pharma A/S AND NB FP Investment II K/S DATED 30/5/2014Convertible Loan Agreement • August 11th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 11th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
This Indemnification Agreement (the “Agreement”) is made and entered into this day of [·], 2014, by and between Forward Pharma A/S, a Danish corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company), and [·] (the “Indemnitee”).
EXECUTION VERSION PATENT TRANSFER AGREEMENT BETWEEN Aditech Pharma AG AND Forward Pharma A/S Dated May 4, 2010Patent Transfer Agreement • August 11th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 12th, 2014 • Forward Pharma a/S • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the 11th day of September, 2014, by and among Forward Pharma A/S, a Danish public limited liability company (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and together with the Company, the “Parties” and each a “Party.”
SHARE PURCHASE AGREEMENT Between Forward Pharma Operations ApS And FWP HoldCo ApS concerning the shares in FWP IP ApS This SHARE PURCHASE AGREEMENT (the "Agreement") was concluded on 22 November 2017 between Forward Pharma Operations ApS CVR-no. 38 75...Share Purchase Agreement • November 22nd, 2017 • Forward Pharma a/S • Pharmaceutical preparations
ContractShareholders Commitment Agreement • January 17th, 2017 • Forward Pharma a/S • Pharmaceutical preparations
SHAREHOLDERS COMMITMENT AGREEMENT dated as of January 17, 2017 (this “Agreement”), among BIOGEN SWISS MANUFACTURING GMBH, organized and existing under the Laws of Switzerland and having its principal place of business at Landys & Gyr Strasse 3, 6300 Zug, Switzerland (“U.S. Licensee”), BIOGEN INTERNATIONAL HOLDING LTD, organized and existing under the Laws of Bermuda, having its registered office at 22 Victoria Court, Hamilton, Bermuda (“Designated Countries Licensee” and together with U.S. Licensee, “Licensee”), and each of THE PARTIES LISTED ON SCHEDULE A ATTACHED HERETO (each, a “Shareholder” and, collectively, the “Shareholders”).
a Danish public limited liability company) [·] American Depositary Shares Representing an Aggregate of [·] Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 9th, 2014 • Forward Pharma a/S • Pharmaceutical preparations • New York
Forward Pharma A/S, a Danish public limited liability company (the “Company”), confirms its agreement with the several Underwriters named in Schedule A hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink Partners LLC (“Leerink”) and Jefferies LLC (“Jefferies”) are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of the American Depositary Shares (the “ADSs”), each ADS representing one of the Company’s ordinary shares, nominal value DKK 0.10 per share (the “Ordinary Shares”), set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [·] additional ADSs solely for the purpose of covering over-al
Biogen Swiss Manufacturing GmbH Biogen International Holding Ltd. c/o Biogen Inc. Cambridge, MA 20142License Agreement • January 17th, 2017 • Forward Pharma a/S • Pharmaceutical preparations • New York
We refer to the proposed Settlement and License Agreement attached hereto as Exhibit A to be entered into by Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and each of the parties listed on Appendix I thereto, to be dated as of the date of this letter agreement (the “License Agreement”). Capitalized terms used and not defined in this letter agreement (the “Agreement”) shall have the meaning ascribed in the License Agreement.
Pledge agreement concerning the shares in FWP IP ApSPledge Agreement • November 22nd, 2017 • Forward Pharma a/S • Pharmaceutical preparations
concerning the shares in FWP IP ApS, a Danish private limited liability company with registration no. (CVR no. 38 75 83 57) having its registered address at Østergade 24A, 1., 1100 Copenhagen K, Denmark (the “Company”).
File no.: 1022720/2454Call Option Agreement • November 22nd, 2017 • Forward Pharma a/S • Pharmaceutical preparations
concerning the shares in FWP IP ApS, a Danish private limited liability company with registration no. (CVR no. 38 75 83 57) having its registered address at Østergade 24A, 1., 1100 Copenhagen K, Denmark (the “Company”).
SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017Settlement and License Agreement • January 17th, 2017 • Forward Pharma a/S • Pharmaceutical preparations • New York
SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) dated as of the Agreement Date (as defined below), among each of the following Parties:
ASSET CONTRIBUTION AGREEMENT concerning the assets, rights, liabilities and obligations of Forward Pharma A/SAsset Contribution Agreement • September 26th, 2017 • Forward Pharma a/S • Pharmaceutical preparations
SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017Settlement and License Agreement • April 18th, 2017 • Forward Pharma a/S • Pharmaceutical preparations • New York
Pursuant to 35 U.S.C. § 135(c), 37 C.F.R. § 41.205, and ¶ 205 of the Standing Order (Paper 2), Junior Party Biogen MA Inc. and Senior Party Forward Pharma A/S hereby give notice that the parties have made a written agreement relating to the Interference.
FORWARD PHARMA A/S Option AgreementOption Agreement • December 13th, 2021 • Forward Pharma a/S • Pharmaceutical preparations
This Option Agreement (this "Agreement") is made and entered into effective as of __________ ___, 20___ by and between Forward Pharma A/S, company registration no. (CVR no.) 28865880, a public limited liability company duly incorporated and organized under the laws of the Kingdom of Denmark (the "Company"), and ________________, an employee of the Company (the "Participant").
STOCK LENDING AGREEMENT Between Nordic Biotech Opportunity Fund K/SStock Lending Agreement • October 9th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
Exhibit 10: Form notice from the Company and the Lender to the Transfer Agent of the redelivery of the Option Lending Shares
shareholders’ agreement forward pharma a/s BETWEEN Nordic Biotech K/S Nordic Biotech Opportunity Fund K/S NB FP Investment K/S AND NB FP Investment II K/S DATE: 8 September 2014Shareholders’ Agreement • September 12th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
Forward Pharma A/S Østergade 24AForward Pharma a/S • January 17th, 2017 • Pharmaceutical preparations
We refer to the proposed addendum to the Patent Transfer Agreement, dated May 4, 2010, between Aditech Pharma AG (“Aditech”) and Forward Pharma A/S (“Forward Pharma” and, together with Aditech, the “Parties”) attached hereto as Exhibit A to be entered into by Aditech and Forward Pharma, to be dated as of the date of this letter agreement (the “Aditech Addendum”). Capitalized terms used and not defined in the body of this letter agreement (the “Agreement”) or Appendix I hereto shall have the meaning ascribed in the Aditech Addendum.
ADDENDUM TO PATENT TRANSFER AGREEMENTForward Pharma a/S • January 17th, 2017 • Pharmaceutical preparations
This addendum, dated as of January 17, 2017 (the “Addendum”), to the Patent Transfer Agreement, including all schedules thereto, dated as of May 4, 2010 (the “Patent Transfer Agreement”)
FRAMEWORK AGREEMENT FORWARD PHARMA A/S BETWEEN Nordic Biotech K/S Nordic Biotech Opportunity Fund K/S BML Healthcare I, L.P. NB FP Investment K/S NB FP Investment II K/S AND Forward Pharma A/S DATED 11/7/2014Framework Agreement • August 11th, 2014 • Forward Pharma a/S • Pharmaceutical preparations
Appendix 4.3.1 (b): Draft minutes of general meeting (authorisation of the Board to issue warrants and shares to employees etc. and adoption of 2014 omnibus equity compensation plan)
IPR SERVICES, ADMINISTRATION, FUNDING AND NOVATION AGREEMENTSettlement and License Agreement • September 26th, 2017 • Forward Pharma a/S • Pharmaceutical preparations • New York
This IPR SERVICES, ADMINISTRATION, FUNDING AND NOVATION AGREEMENT (this “Agreement”), effective as of June 30, 2017, is made and entered into between Forward Pharma A/S, a Danish limited liability company (“Forward Pharma”), Forward Pharma Operations ApS, a Danish limited liability company and wholly owned direct subsidiary of Forward Pharma (“New SubCo”), FWP IP ApS, a Danish limited liability company and wholly owned direct subsidiary of New SubCo (“SubCo 1”), Biogen Swiss Manufacturing GmbH, a Swiss limited liability company (“U.S. Licensee”) and Biogen International Holding Limited, a Bermudan private limited company (“Designated Countries Licensee” and together with the U.S. Licensee, “Licensee” and each of the foregoing, a “Party” and collectively, the “Parties” hereunder). Capitalized terms used and not defined in the body of this Agreement shall have the meaning ascribed in the License Agreement (as defined below).
Depositary ReceiptsLetter Agreement • April 24th, 2020 • Forward Pharma a/S • Pharmaceutical preparations • New York
